Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence of in vivo priming by tumor cells

Journal of Immunotherapy

Volumn 19, Issue 4, 1996, Pages 266-277

  Marincola, Francesco M ^a,b   Rivoltini, Licia ^a,c   Salgaller, Michael L ^a   Player, Maryanne ^b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Istituto Tumori   (Italy)

Author keywords

Immunotherapy; MART 1; Mclanoma

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL;

EID: 0029835516     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199607000-00003     Document Type: Article

References (38)

1. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
2. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc NatI AcadSci USA 1994;91:3515-9.
3. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl AcadSci USA 1994;91:6458-62.
5. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments], J Exp Med 1994;180:35-42.
6. van der Bruggen P, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994;24:3038-43.
7. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
8. Salgaller ML, Afshar A, Marineóla FM, Rivoltini L, Kawakami Y, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp 100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 1995;55:4972-9.
9. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
10. Visseren MJW, van Elsas A, van der Voort EIH, et al. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995;154:3991-8.
11. Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-9.
12. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med 1993;177:989-98.
13. Burnet M. The clonal selection theory of acquired immunity. Cambridge: University Press, 1959.
14. Hooper DC, Taylor RB. Specific helper T cell reactivity against autologous erythrocytes implies that self tolerance need not depend on clonal deletion. Eur J Immunol 1987; 17: 797-802.
15. Ohashi PS, Oehen S, Buerki K, et al. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-17.
16. Johnson JG, Jenkins MK. The role of anergy in peripheral T cell unresponsiveness. Life Sci 1994;55:1767-80.
17. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry [see comments]. Science 1992; 255:1261-3.
18. Carbone FR, Moore MW, Sheil JM, Bevan MJ. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 1988;167:1767-79.
19. Schild H, Rotzschke O, Kalbacher H, Rammensee HG. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990;247:1587-9.
20. Rivoltini L, Baracchini KC, Viggiano V, et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res 1995;55:3149-57.
21. Elson CJ, Barker RN, Thompson SJ, Williams NA. Immunologically ignorant autoreactive T cells, epitope spreading and repertoire limitation. Immunol Today 1995;16:71-6.
22. Duhra P, Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. CUn Exp Dermatol 1991;16:303-5.
23. Mehta N, Ramming K, Richards JM. Treatment-induced vitiligo during successful chemoimmunotherapy for melanoma. Proc Annu Meet Am Soc Clin Oncol 1991; 10:A1018.
24. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides [see comments]. Nature 1992;356:443-6.
25. Cerundolo V, Alexander J, Anderson K, et al. Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 1990;345:449-52.
26. Moss DJ, Misko IS, Burrows SR, Burman K, McCarthy R, Sculley TB. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature 1988; 331:719-21.
27. Hopkins KA, van Leeuwen A, Tardiff GN, LeFor WM. Lymphotoxicity testing. In: Zachary AA, Teresi GA, eds. ASHI laboratory manual. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics, 1990:195-9.
28. Adams SD, Marineóla FM, Shamamian P, Simonis TB, Davey RJ. HLA class I typing of tumor cell lines using fluorescence activated cell sorting (FACS) and complement mediated cytotoxicity (CDC). Hum Immunol 1994;37 (suppl): 149.
29. Marineóla FM, Shamamian P, Alexander RB, et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 1994;153:1225-37.
30. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci USA 1993;90:2842-5.
31. Krausa P, Brywka M, Savage D, et al. Genetic polymorphism within HLA-A*02: significant allelic variation revealed in different populations. Tissue Antigens 1995; 45: 223-31.
32. Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 1995;95:341-9.
33. Rivoltini L, Loftus DJ, Barracchini K, et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. J Immunol 1996;153:3882-91.
34. Margolin KA, Doroshow JH, Akman SA, et al. Phase I trial of interleukin-2 plus gamma-interferon. J Immunother 1992; 11:50-5.
35. Coulie PG, Somville M, Lehmann F, et al. Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells. Int J Cancer 1992; 50: 289-97.
36. Chen Y-T, Stockert E, Tsang S, Coplin KE, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92: 8125-9.
37. Ferrone S, Marineóla FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
38. Luscher U, Filgueira L, Juretic A, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer 1994;57:612-9.